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Pituitary adenylate cyclase activating polypeptide (PACAP) is a multifunctional neuro-
peptide with widespread occurrence throughout the body including the gastrointestinal 
system. In the small and large intestine, effects of PACAP on cell proliferation, secretion, 
motility, gut immunology and blood flow, as well as its importance in bowel inflammatory 
reactions and cancer development have been shown and reviewed earlier. However, no 
current review is available on the actions of PACAP in the stomach in spite of numerous 
data published on the gastric presence and actions of the peptide. Therefore, the aim 
of the present review is to summarize currently available data on the distribution and 
effects of PACAP in the stomach. We review data on the localization of PACAP and 
its receptors in the stomach wall of various mammalian and non-mammalian species, 
we then give an overview on PACAP’s effects on secretion of gastric acid and various 
hormones. Effects on cell proliferation, differentiation, blood flow and gastric motility are 
also reviewed. Finally, we outline PACAP’s involvement and changes in various human 
pathological conditions.
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iNTRODUCTiON
PACAP was isolated as a neuroendocrine regulator of the hypothalamo-hypophyseal system in two 
forms, PACAP1–27 and PACAP1–38, with 27 and 38 amino acid residues, respectively. PACAP and 
VIP belong to the same peptide family (VIP-secretin-glucagon), based on the structural similarity 
between the shorter form of PACAP and VIP. Later PACAP was shown throughout the body with 
a diverse array of functions, including the gastrointestinal system. VIP has long been known as a 
gastrointestinal peptide, but shortly after the isolation of its related peptide many, partially overlap-
ping, gastrointestinal effects of PACAP have also been described. PACAP, similarly to VIP, occurs 
along the entire digestive tract, and both peptides are abundantly expressed in the enteric nervous 
system (ENS) and enteroendocrine cells, influencing secretion, motility and reflexes. PACAP acts 
through its specific PAC1 receptor and the VPAC1 and 2 receptors, which also bind VIP with similar 
affinity (1).
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In the small and large intestine, PACAP is involved in several 
biological processes. Its effects on cell proliferation, secretion, 
motility, gut immunology, and blood flow have been shown 
(1–3). Under pathological circumstances, it has been shown that 
PACAP decreases inflammatory reactions both in the small and 
in the large intestine, while lack of PACAP is associated with 
increased inflammatory reactions and colon cancer development 
(4–6). The intestinal effects of PACAP have been reviewed several 
times by different authors (7–10). However, no current review 
is available on the actions of PACAP in the stomach in spite of 
dozens of articles published on the gastric presence and actions 
of the peptide. Therefore, the aim of the present review is to sum-
marize currently available data on the distribution and effects of 
PACAP in the stomach.
PReSeNCe AND DiSTRiBUTiON OF 
PACAP AND iTS ReCePTORS iN THe 
STOMACH
The presence and distribution of PACAP have been studied in 
several species with different methods, and all have found PACAP 
expression in the stomach wall, with some qualitative and quan-
titative differences between species and methods used (11). Soon 
after its discovery, a radioimmunoassay (RIA) study described the 
distribution of PACAP in various tissues of the rat and found that 
PACAP1–38 was the dominant type in mammalian tissues. They 
could detect PACAP also in the gastrointestinal tract, with stom-
ach, duodenum and jejunum showing higher levels compared to 
other parts of the intestinal system (12). In another study in rats, 
Hannibal et al. found high levels of PACAP1–38 in the stomach 
by RIA and lower levels of PACAP1–27 and PACAP-related 
protein. There was no difference between levels measured in the 
esophagus and antrum/fundus parts of the stomach, but higher 
levels were measured in the small intestine (11). The dominance 
of PACAP1–38 was also confirmed in the antrum part of the 
porcine stomach by another RIA study, with PACAP1–27 just 
reaching detection limit (13). The authors measured mucosal and 
muscularis extracts separately and found slightly higher levels in 
the muscularis part.
The first comparative immunohistochemical description of 
PACAP1–27-like immunoreactivity in the alimentary canal of 
several species came from Sundler et al. (14), who found immu-
nopositivity in nerve fibers in the wall of the gastrointestinal 
tract of all mammalian species examined, namely mouse, rat, 
hamster, guinea pig, ferret, cat, pig, sheep and man. In the gastric 
mucosa, they observed delicate PACAP-immunoreactive fibers in 
the mouse, rat, hamster and human, but not in the other species 
examined. Fine varicose fibers were found in the mucosa (both 
oxynthic and pyloric parts) and also in the muscularis layer in the 
rat stomach. Moderate number of PACAP-containing fibers was 
seen in the submucous ganglia, while numerous nerve fibers as 
well as immunopositive nerve cell bodies in the myenteric ganglia 
(11). PACAP is frequently colocalized with the sensory neuropep-
tide CGRP and also with VIP. In pigs, PACAP-immunoreactivity 
was described in beaded nerve fibers in all layers of the antrum, 
with higher number in the muscular and submucosal layers than 
in the mucosa. Furthermore, immunoreactivity was observed in 
nerve cell bodies of the myenteric ganglia, but not in the submu-
cosal plexus (13). Colocalization with VIP was observed both in 
the fibers and in the ganglionic cells and some fibers costored 
CGRP, especially those innervating submucosal blood vessels 
(13). In the mucosa, only few PACAP positive nerve fibers could 
be found, mainly around blood vessels and some associated with 
basal glandular cells (13).
Other studies have also confirmed these findings. Kantor 
et al. (15) could detect PACAP-specific mRNA in the oxynthic 
mucosa of the rat stomach with RT-PCR. PACAP mRNA was also 
demonstrated by in situ hybridization in a few nerve cell bodies 
in the myenteric ganglia indicating some intrinsic synthesis of the 
peptide (11). Studying further the origin of PACAP-ergic nerves 
Hannibal et  al. performed capsaicin-induced denervation as 
well as surgical denervation. They found that neonatal capsaicin 
treatment reduced the concentration of PACAP in the stomach 
by about one-third. This was mainly confined to the oxynthic part 
of the submucosa, where a reduced number of immunopositive 
nerve fibers was observed, while fibers remained unaffected in 
the mucosa, muscularis and myenteric ganglia. After surgical 
extrinsic denervation, a modest decrease was observed. These 
data proved that the origin of PACAP in the stomach wall is dual: 
both intrinsic and extrinsic. The extrinsic innervation is most 
probably sensory, also supported by the observations of PACAP 
in the jugular-nodose ganglion of the vagus nerve and dorsal root 
ganglia (16–18).
PACAP  immunoreactivity was also studied in the sheep diges-
tive tract (19). Fibers were mainly detected in the muscular layer 
of the stomach, including cardia, corpus, antrum, and pylorus, 
with pyloric sphincter showing very strong PACAP-ergic inner-
vation (19). Scarse immunolabeled fibers were detected in the 
mucosa, mainly in the lamina muscularis mucosae. Fibers and 
few perikarya were detected in myenteric ganglia (19). Presence 
of PACAP in the stomach wall has also been confirmed in cats 
(20). In the guinea pig, myenteric fibers showed weak immu-
noreactivity, together with lamina propria around glands and 
submucosal blood vessels, with weaker expression than in other 
mammalian species (21). PACAP immunoreactivity showed 
similar pattern in another rodent, Mastomys stomach, where 
PACAP was found in the oxynthic mucosa between the glands 
and in the submucosa (22).
Based on the very limited available data, PACAP occurs also 
in the human stomach, similarly to the distribution in other 
mammals. As mentioned earlier, Sundler et  al. (14) observed 
delicate PACAP1–27-like immunoreactive fibers in the stomach. 
Vincze et al. have described first the presence of PACAP in the 
normal human stomach (20). In addition to the few PACAP-
positive fibers in the mucosa, numerous cells contain PACAP in 
the glands of the fundus and corpus, and less in the cardia and 
pylorus. Electron microscopical observations showed that mainly 
the parietal cells contained perinuclear PACAP immunoreactiv-
ity (20). During fetal development, PACAP immunoreactivity 
appears in the human gastric glands, of both corpus and pylorus, 
around the 18th to 20th intrauterine weeks (23).
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The presence of PACAP has also been investigated in the 
alimentary tract, including the stomach, of several non-mam-
malian species. For example, PACAP/GHRH-like mRNA could 
be detected in the stomach of catfish (24). PACAP and receptor 
transcripts have been found in another fish [tilapia (25)]. In 
zebrafish, immunohistochemistry established the presence of 
gut neurons expressing PACAP in the proximal part of the 
developing gut from the first stage investigated (2 days postfer-
tilization) and before regular motility was observed. At 5 days 
postfertilization, PACAP reduced the regular propagating wave 
frequency of gut motility. This suggests that both excitatory 
and inhibitory pathways develop at an early stage in the gut, 
independent of exogenous feeding. This supports physiological 
results that gut motility is under neuronal control during the 
period when regular motility patterns develop (26). PACAP 
mRNA has also been identified in the olive flounder pylorus 
(27). Among reptiles, Valiante et  al. (28) found mRNA for 
PACAP in gastric glands with in situ hybridization and PACAP 
peptide with immunohistochemistry as well as immunoreac-
tivity with antisera against all three PACAP receptors in the 
lizard stomach. In frog species, Olsson showed the presence 
of PACAP in the entire gastrointestinal tract, including the 
stomach, of the African clawed frog (29). He showed immu-
nopositivity in all layers of the stomach, in the endocrine cells 
of the mucosa, and in nerve fiber bundles and ganglionic cells 
of the myenteric plexus. PACAP and VIP colocalization was 
observed in most places.
In birds, several studies have shown the presence of PACAP 
in the proventriculus (glandular part of avian stomach) and 
gizzard. Sundler et  al. (14) studied PACAP1–27-like immu-
noreactivity in the digestive tract of chicken in addition to 
several mammalian species (see above). In the proventriculus, 
numerous PACAP-immunoreactive endocrine cells could be 
observed which were identical to the serotonin-containing cells 
storing gastrin-releasing peptide (14). Simon et al. (30) described 
PACAP gene expression increase in the glandular stomach in 
case of food restriction. In addition, nerve elements in other 
layers also contained immunoreactivity. Studying the ontogeny 
of PACAP-containing elements, Salvi et  al. (31) found the first 
PACAP-immunoreactive elements at embryonic days 4.5–5 in 
the mesenchymal bud of the proventriculus/gizzard. After the 
pharyngeal appearance at E4, PACAP elements formed a weak 
network in the marginal mesenchymal zone of the stomach bud, 
followed by gradual appearance in myenteric and submucous 
plexuses (31). PACAP immunoreactivity has also been studied in 
another avian species by Mirabella et al. (32–34). The presence of 
both PACAP1–38 and PACAP1–27 was demonstrated, the for-
mer being the predominant form, in the gastrointestinal tract of 
the duck (32). They found PACAP immunoreactivity in neurons 
and fibers of the ENS, in endocrine cells and in the gut-associated 
lymphoid tissue, suggesting multiple roles of the peptide in the 
duck gastrointestinal system. The majority of mucosal ganglion 
cells in the proventriculus were shown to contain PACAP (33). 
In pigeons, the coexistence of PACAP/VIP was revealed in the 
stomach in NADPH-positive myenteric neurons, implying that 
the nitrergic nerve population of the pigeon gastrointestinal 
tract takes part in regulation of muscle motility as an inhibitory 
descending nerve pathway (34).
Even invertebrates contain PACAP-like immunoreactivity 
in their alimentary canal, including the areas corresponding to 
mammalian foregut/stomach regions. PACAP1–27 has been 
shown to be the dominant form of the peptide according to a 
RIA study, but immunoreactivity to both peptides could be 
shown in the foregut/gizzard regions of the earthworm Lumbricus 
polyphemus (35). PACAP-immunoreactive elements have been 
identified mainly in the ganglia supplying the alimentary canal 
in three annelid species: Lumbricus terrestris, Eisenia fetida, and 
Lumbricus polyphemus (36, 37). This has also been shown during 
earthworm development, along with the appearance of PAC1 
receptor-like immunoreactivity in the subesophageal and other 
ventral cord ganglia (38, 39). Interestingly, and in concert with 
the well-known regeneration-promoting effect of PACAP (40, 
41), significant increases in the concentration of PACAP-like 
compounds were found in the body wall, alimentary canal, and 
in coelomocytes during regeneration. The most characteristic 
morphological feature was the accumulation of immunolabeled 
neoblasts in the injured tissues, especially in the ventral nerve 
cord ganglion that initiates and mediates regeneration processes, 
including that of the digestive tract (42). Although no functional 
data are available, taken together, these morphological observa-
tions indicate that PACAP (or a PACAP-like peptide) occurs early 
during phylogeny, and is present not only in vertebrates, but also 
in the invertebrate alimentary tract.
Early receptor binding studies already detected PACAP bind-
ing in the stomach (43). Receptors for both PACAP and VIP 
have been identified in the stomach wall. In porcine antrum, 
mRNA for PAC1 and VPAC1 and 2 was identified (13), PAC1 
and VPAC2 were mainly expressed in the muscular, but not in 
the submucosal/mucosal layers, while VPAC1 was found in all 
layers (13). In the gastric smooth muscle of guinea pigs VPAC2 
receptor was found (44). Other studies have also shown PACAP 
receptors in different layers of the stomach. For example, VPAC2 
receptors have been detected in the smooth muscle cells isolated 
from rabbit and guinea pig stomach (45), and others also detected 
VPAC2 receptors in the muscularis mucosae and the main 
muscularis layers of the mouse stomach, while no VPAC2 was 
found in other layers (46). PACAP binding has been shown in 
various pharmacological studies investigating motility (47–49). 
Enterochromaffin-like (ECL) cells express PAC1 receptor, and it 
is believed that PACAP from the myenteric neurons acts on these 
cells (50–52). It is well supported by some studies that ECL cells 
express PAC1 receptor, but not the VPAC receptors in rats and 
mice (53, 54), although all three receptors were found by others 
in Mastomys (22). All splice variants of the PAC1 receptors have 
been described on ECL cells (55).
The wide distribution of PACAP and its receptors in secretory 
cells, in the nerves innervating different gastric layers and around 
blood vessels supplying the stomach (summarized in Table  1) 
suggests that PACAP plays various roles in gastric secretion, 
motility, and blood flow. In the following sections, we summarize 
currently available data on the different effects of PACAP in the 
stomach (Figure 1).
TABle 1 | Presence and main distribution sites of PACAP and its receptors in the stomach of various species.
Species localization of PACAP localization of PACAP 
receptor(s)
Reference
veRTeBRATe Dominant form: 1–38
Mammalian
Cat Nerve fibers of myenteric ganglia and muscularis (14, 20)
Ferret Nerve fibers in gastrointestinal wall (14)
Guinea pig Myenteric fibers, lamina propria, submucosal blood vessels, nerve fibers of muscularis Gastric smooth muscle: 
VPAC2
(14, 21, 44, 45)
Hamster Nerve fibers in mucosa, myenteric ganglia and muscularis (14)
Human Gastric glands, mainly parietal cells, nerve fibers of mucosa, myenteric ganglia, and muscularis (14, 20, 23)
Mastomys Oxynthic mucosa and submucosa PAC1, VPAC1 and 2 on 
enterochromaffin-like cells
(22)





Pig Nerve fibers in all layers of antrum, nerve cell bodies of myenteric ganglia, muscularis Muscularis of antrum: PAC1, 
VPAC2
All layers of antrum: VPAC1
(13, 14)
Rabbit Gastric smooth muscle: 
VPAC2
(45)
Rat Submucous and myenteric ganglia, mucosa, submucosa, muscularis PAC1 on enterochromaffin-
like cells
(11, 14, 15, 
50–52, 54)
Sheep Muscularis of cardia, corpus, antrum and pylorus, muscularis mucosae, fibers, and  
perikarya of myenteric ganglia
(14, 19)
Non-mammalian
Catfish Stomach wall (24)
Chicken Endocrine cells in proventriculus, proventriculus, mesenchymal bud of proventriculus/gizzard, 
myenteric, and submucous plexus
PAC1 in proventriculus (14, 30, 31)
Duck Neurons and fibers of enteric nervous system, mucosal ganglionic cells in proventriculus (32, 33)
Frog All layers of gastric wall, endocrine cells of mucosa, myenteric plexus (29)
Lizard Gastric glands PAC1, VPAC1, VPAC2 (28)
Olive flounder Pylorus (27)
Pigeon Myenteric neurons (34)
Tilapia PAC1 (25)
Zebrafish Gut neurons in proximal part of developing gut (26)
iNveRTeBRATe Dominant form: 1–27
Lumbricus 
polyphemus
Foregut, ganglia of alimentary canal (35–37)
Lumbricus terrestris
Eisenia fetida
Ganglia of alimentary canal (36, 37)
4
Reglodi et al. Gastric Distribution and Effects of PACAP
Frontiers in Endocrinology | www.frontiersin.org March 2018 | Volume 9 | Article 90
eFFeCTS OF PACAP iN THe STOMACH
effects on Gastric Secretion
As one of its main actions, PACAP leads to increases in cAMP 
levels also in the stomach (56). Interestingly, this action could 
not be shown in isolated stomach wall preparation under unchal-
lenged conditions but was markedly potentiated in the presence of 
phosphodiesterase inhibitors, and it was four times greater than in 
the presence of the inhibitor alone, without PACAP addition (56).
A lot of work has been done in order to clarify the role of 
PACAP on acid secretion (Figure  1). In the beginning, several 
contradictory studies were published, some reporting stimulatory 
effects on acid secretion, while others inhibitory. The primary site 
for acid secretion is the parietal cells situated in the gastric corpus. 
In the cephalic phase, vagal afferents stimulate acid secretion 
through the release of acetylcholine and PACAP. The gastric phase 
of acid secretion is regulated by gastrin released from G cells, by 
histamine from ECL cells and somatostatin from D cells (7). The 
ECL cells control parietal cells by releasing histamine in their 
immediate vicinity. According to a number of studies, gastrin and 
PACAP stimulate histamine secretion from isolated ECL cells, 
while somatostatin and galanin inhibit stimulated secretion (57).
FiGURe 1 | Summary of the effects of PACAP in stomach.
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Plenty of studies show stimulatory actions of PACAP on 
acid secretion. PACAP increases acid secretion directly and 
also through stimulating histamine release (56). The histamine-
releasing effect of PACAP in ECL cells has been shown in vitro 
(55, 58) and in stomach wall preparations (59). It has also been 
demonstrated that the PACAP-evoked secretion of histamine 
depends on Ca2+ entry (60). Several other studies have proven 
that through its receptor, PACAP activates calcium signaling and 
histamine release from ECL cells (55, 61, 62). Not only ECL cells 
respond to PACAP with elevated calcium levels, but also adjacent 
parietals cells (63). The PACAP-induced increase in gastric acid 
secretion can be blocked by the phosphodiesterase 4 inhibitor 
rolipram, which inhibits the degradation of cAMP (56).
The action of PACAP on gastric acid secretion has some con-
troversial aspects. Although many studies describe that PACAP 
stimulates gastric acid secretion, the peptide is also known to 
stimulate somatostatin release from D cells (53, 56, 64), thus, 
it decreases gastric acid secretion. Li et  al. described that the 
inhibition on gastric acid secretion in rat stomach by PACAP is 
mediated by secretin, somatostatin, and prostaglandin E2 (PGE2) 
(65, 66). Similarly, Mungan et al. found that intravenous PACAP 
inhibits pentagastrin and histamine-induced acid secretion in 
conscious pylorus-ligated rats and in gastric fistula rats, while 
no effect on carbachol-stimulated or basal secretion in pylorus 
ligated rats (67). Others have confirmed this observation: in wild-
type urethane-anesthetized mice, PACAP1–38 did not affect the 
low basal acid secretion, but inhibited the acid response to penta-
gastrin, histamine, and bethanechol (64). Also, the involvement 
of somatostatin has been confirmed in this action, as in conscious 
wild-type mice, but not in somatostatin receptor 2 knockout 
mice, PACAP1–38 inhibited gastric acid secretion induced by 
2-h pylorus ligation (64).
The contradictions have been partially resolved by studies 
showing that ECL cells possess PAC1 receptors, through which 
PACAP increases acid secretion, but also stimulates somatostatin 
release from D cells via VPAC1 receptor inhibiting gastrin and 
acid secretion through a less robust pathway (7, 54, 68–70). 
Pisegna’s group hypothesized that in the neural phase, PACAP 
increases acid secretion prior to meal ingestion, but later it 
inhibits it via stimulating the gastrin-inhibitory somatostatin 
release (7, 54). This theory is supported by the observations in 
PAC1-deficient mice: knockout mice develop gastric hyperse-
cretion accompanied by elevated circulating gastrin levels and 
higher gastrin mRNA levels in the mucosa (53) in contrast to 
the findings of Mungan et al. (67), who detected no elevation in 
serum gastrin levels after intravenous PACAP administration. 
PAC1 receptor-deficient mice have elevated basal gastric output 
(nearly threefold increase compared to wild-type mice), have 
higher threshold to the effects of exogenous gastrin, but have an 
intact histamine stimulatory pathway (53). Another study has 
shown that microinfusion of PACAP into rat gastric submucosa 
produces a transient histamine response, in contrast to gastrin 
that shows a sustained action (71). The authors suggest that 
this transient response reflects receptor desensitization and/or 
depletion of secretory products (72). These observations can 
have translational value, as for example, PAC1 receptor knockout 
mice have been suggested to be a model for the human Zollinger-
Ellison syndrome (65, 68). Also, the PACAP-driven regulatory 
mechanisms could play a role in several other clinical conditions 
related to disturbed gastric acid secretion (68).
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As already mentioned earlier, PACAP affects release of 
several other factors. Stimulatory effects on somatostatin have 
been shown in porcine antrum where PACAP decreases gastrin 
secretion (13). ECL cells also produce pancreastatin in addition 
to histamine (71, 72). PACAP has been shown to evoke release of 
pancreastatin, a chromogranin A-derived peptide, with actions 
like inhibition of insulin secretion, pancreatic enzyme release, 
and gastric acid secretion (73). The PACAP-evoked release of 
pancreastatin can be inhibited by prostaglandins (72), galanin, 
misoprostol, and somatostatin (74). The stimulatory effects of 
PACAP on other substances have also been revealed. For exam-
ple, PACAP stimulates the release of gastrin releasing peptide, 
VIP, and substance P (13). The release of somatostation, GRP, 
VIP and SP was not inhibited by PACAP6–38, suggesting the 
involvement of VPAC1 receptors, on which PACAP6–38 has no 
effect (13). PACAP also stimulates secretin release along with 
somatostatin and prostaglandins (65, 66, 75). PACAP is able 
to induce pepsinogen release from chief cells of the guinea pig 
(76). In isolated chief cells, PACAP and VIP binding sites were 
identified and PACAP1–38 induced biphasic pepsinogen release 
with the same potency as PACAP1–27 and VIP did. Li et al. (65) 
examined the inhibitory effect of PACAP1–27 on gastric acid 
secretion and its mechanism. It dose-dependently hindered both 
basal and pentagastrin-induced acid secretion. This inhibitory 
effect could be reversed using antisecretin, antisomatostatin 
serum, and indomethacin indicating that PACAP’s effect involves 
local release of secretin, somatostatin, and PGE2.
effects on Cell Proliferation and 
Differentiation
In isolated rat gastric ECL cells, Oh et  al. (54) demonstrated 
a dose-dependent stimulation of proliferation, with 100  nM 
PACAP causing a maximum, 30% increase. Another study has 
also observed that PACAP stimulates proliferation of Mastomys-
derived ECL cells, with 100 times more potency than VIP (22, 
52). This could be inhibited by PACAP antagonist. In rabbit 
smooth muscle cells isolated from the antrum, no effect has 
been shown on the cell number in cultures, in contrast to colonic 
muscle cells, where PACAP inhibited the serum induced increase 
in cell number (77). This shows region-specific effects of PACAP 
on cell proliferation in the gastrointestinal tract. In PAC1 receptor 
deficient mice, hypertrophic gastric mucosa was observed with 
greater mucosal thickness resulting from greater gland height, 
but no difference in the pit sizes (53). This was accompanied by an 
increased cell mass, especially with increased parietal cell num-
ber, while total neuroendocrine cell number and D cell number 
was unaltered (53) (Figure 1).
effects on Motility
PACAP is known to have actions on smooth muscle of inner 
organs and blood vessels (78). In the stomach fundus, effects on 
motility resemble those in the esophagus (10, 47, 48). PACAP 
exerts similar, relaxant activity in the body and fundus of the 
stomach. In rat longitudinal gastric fundus muscle strips, a 
relaxant effect was produced by VIP, PACAP1–27, and secretin 
(79). Similarly, PACAP exerts relaxant activity on circular muscle 
strips from rat gastric fundus (80) and in the mouse antrum (81). 
In guinea pig gastric fundus, VIP, PACAP1-27 and PACAP1-38 
induced concentration-dependent relaxation that was partly 
inhibited by the antagonists VIP10–28 and PACAP6–38 and 
the NO synthase inhibitor NG-nitro-l-arginine (l-NNA). Only 
relaxation induced by PACAP1–27 and PACAP1–38 was partly 
inhibited by apamin (47). Furthermore, electrical-field stimula-
tion induced PACAP release. The authors conclude that the 
inhibitory transmission in guinea pig gastric fundus represents 
the combined actions of VIP, PACAP and NO released from 
nerve terminals and NO generated in muscle cells, which possess 
VPAC receptors, but no PAC1 receptor (47). PACAP binding was 
shown in dispersed rabbit gastric muscle cells, where PACAP, 
like VIP, stimulated cytosolic-free calcium and the formation of 
l-[3H]-citrulline, NO-3/NO-2, cGMP, and cAMP and induced 
relaxation (48). According to this latter study, the action of 
PACAP is mediated via the common VPAC receptors (48). 
PACAP also inhibits relaxation in the porcine lower esophageal 
sphincter (82). A recent study has confirmed the relaxant activity 
of PACAP in a dose dependent manner in mouse gastric fundus, 
while PACAP6–38 suppresses gastric relaxation (83). Evidence 
has also been published for the involvement of VIP/PACAP 
receptors in the afferent pathway mediating surgery-induced 
fundic relaxation in the rat (84) (Figure 1).
The role of endogenous PACAP in the regulation of motility 
is supported by the inhibition of the sustained relaxation by a 
PACAP receptor antagonist, PACAP6–38 (85). Furthermore, 
muscle strips prepared from PACAP knockout mice showed 
decreased level of sustained relaxation, which was about one-half 
of that observed in wild-type mice (85). PACAP6–38 inhibited 
electrical field stimulation-induced sustained relaxation (33.5% 
of control) in PACAP knockout mice. These findings were 
subsequently confirmed by others showing that mice deficient in 
PACAP have decreased relaxation in the stomach (86).
Pyloric sphincter muscle function is of utmost importance in 
gastric emptying, and its regulation is very complex, including 
regulation through nitric oxide, ATP in concert with nonadren-
ergic and noncholinergic transmission (87). Effects of PACAP on 
pyloric motility are somewhat contradictory. PACAP has been 
shown to increase motility of isolated perfused porcine antrum 
preparations (13). This could be blocked by PACAP6–38, which 
had no effect when applied alone. The relaxation in other parts of 
the stomach is not contradictory to the constriction in the pyloric 
part, since sphincter muscles in the GI tract are often antagonisti-
cally innervated or regulated. However, contradictory findings 
have also been reported. In dogs, intravenous administration of 
PACAP did not cause a change in antral motility using chronically 
implanted antral force transducers (88). Similarly, Ishiguchi et al. 
(87) found that lower concentrations of VIP and PACAP (nM) 
had no effect on isolated pyloric strips, only higher concentrations 
inhibited phasic contractions. Parkman et al. (49) also reported 
that VIP, PACAP1–38 and PACAP1–27 inhibited pyloric muscle 
in rabbit pylorus muscle strips. They also found an inhibitory 
effect of PACAP6–27 on both PACAP and VIP-induced relaxa-
tion, suggesting that PACAP and VIP act on the same receptor 
(49). In vivo, intravenous administration of PACAP (0.3–3 nmol/
kg) caused significant relaxations of the rat pylorus suggesting 
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that PACAP acts as inhibitory neurotransmitter in the rat pylorus 
and regulates gastric emptying (89). These discrepancies may be 
due to differences in species or experimental paradigms (13).
eFFeCTS OF PACAP ON GASTRiC  
BlOOD FlOw
PACAP-immunoreactive fibers are often observed around and 
in the walls of blood vessels. The general vasodilatory action of 
PACAP is well established in several species and experimental 
models (78, 90–93). This was also described for the stomach 
wall (13). Especially rich PACAP-ergic innervation could be 
observed in the submucosa, but the few PACAP-ergic nerve fibers 
observed in the mucosa were associated mainly with blood ves-
sels, indicating a potential role in the blood supply of the stomach 
(13). Indeed, it has been confirmed that both PACAP1–27 and 
PACAP1–38 increase gastric blood flow, shown in the left gastric 
artery of dogs (94, 95), where PACAP resulted to be a potent 
vasodilator, stronger than VIP, in the gastric arterial bed in vivo. 
These studies applied the peptides intravenously in conscious 
dogs, previously implanted with flowmeters. The authors con-
ducted similar experiments with PACAP fragments. They showed 
that C-terminal deletions or changing single amino acids in the 
N-terminal did not cause a change in the vasodilator capacity, 
but substituting amino acids 4 and 5 significantly changed the 
biological activity. Responses of the left gastric artery to Ala4, 
Val5-PACAP1–27 and VIP were similar, demonstrating that 
positions 4 and 5 are the key N-terminal residues for PACAP1–27 
(94). These data indicate a physiological role of the peptide in the 
regulation of gastric blood flow.
CHANGeS OF PACAP eXPReSSiON 
UNDeR PHYSiOlOGiCAl AND 
PATHOlOGiCAl CONDiTiONS
Increased PACAP1–38 release has been observed in the porcine 
antrum upon vagus nerve stimulation and capsaicin treatment 
(13). As neonatal capsaicin treatment decreased PACAP content 
in rat stomach, PACAP is probably released from sensory nerve 
terminals (11). These observations are consistent with other stud-
ies in visceral organs, for example, similar results were obtained 
in the trachea: both capsaicin and electrical-field stimulation 
increased PACAP-release (96). PACAP or receptor upregulation 
has been observed in a few other conditions in the stomach: for 
example, CCK knockout mice show upregulated PACAP receptor 
expression in the mucosa, possibly indicating a compensatory 
process (97).
PACAP iN THe DORSAl vAGAl  
NUCleUS iN GASTRiC PATHOlOGiCAl 
CONDiTiONS
PACAP can be observed under normal conditions in approxi-
mately 30% of the neurons in the dorsal vagal nucleus projecting 
to the prepyloric region in pigs (98). According to several studies, 
PACAP is one of the main neuropeptides in this nucleus, as its 
levels are higher under normal conditions than those of other 
examined neuropeptides (98, 99). In acetylsalicylic acid-induced 
gastritis, the number of PACAP-expressing neurons in the dorsal 
vagal nucleus increases by almost 50% in addition to de novo 
appearance of numerous other peptides, including VIP and 
galanin. These data suggest that neuronal PACAP is included in 
the mediation of the neural response to stomach inflammation 
(99). Similar results were obtained after partial gastric resec-
tion, a model of traumatic neuronal injury of the stomach: the 
number of PACAP-expressing neurons increased by 45%, along 
with increases of other neuropeptides (98). The authors suggest 
that the upregulation of PACAP implies its trophic and protective 
role in these gastric pathological conditions (98). These actions 
seem to be generally present in the digestive tract, as increases 
in PACAP-expressing neurons in the intestinal ganglia were 
reported both after axotomy and inflammation in the descending 
colon, in contrast to VIP, the levels of which did not change in 
these models (100, 101).
PACAP iN GASTRiTiS AND UlCeR
As PAC1 receptor deficient mice develop higher gastric acid 
production accompanied by gastric mucosal hypertrophy, it is 
suggested that the PACAP/PAC1 system plays an important role 
in gastric acid secretion not only under normal, but also under 
diseased conditions (53). Indeed, an earlier study found altered 
PACAP tissue expression during ulcer healing in rats (102). In a 
model of experimental ulcer, induced by local injection of acetic 
acid, PACAP and VIP immunohistochemistry was performed 
during the healing process. Starting on day 1, a marked depletion 
of PACAP immunoreactivity in nerve fibers at the margin of the 
ulcer was observed, again observed on days 10 and 15 (102). This 
was in contrast to VIP immunoreactivity, which did not show any 
alterations during the ulcer healing process. Immunoreactivity 
was also studied in the smooth muscle underlying the ulcer, where 
an upregulation of PACAP and VIP could be observed from day 
10, along with an upregulation of PACAP and VIP mRNA in the 
myenteric ganglia in the ulcer’s neighborhood (102). This shows 
that neuronal PACAP depletion was transient and fully revers-
ible. The authors argue that the selective decrease of PACAP at 
the ulcer margin might be due to either excessive release or a 
decrease in synthesis. Duodenal ulcers are linked to gastric acid-
induced lesions and PACAP has been shown to have protective 
effects also in a duodenal ulcer model (103). The peptide is a 
known stimulant of duodenal bicarbonate secretion (104–107) 
and thus, can protect against the irritant effects of gastric acid. 
Indeed, intravenous bolus injection or infusion of PACAP1–27 
increased duodenal bicarbonate secretion even in the presence of 
mepirizole, without an effect on acid secretion, and significantly 
reduced the severity of duodenal lesions (103).
PACAP AND STOMACH CANCeR
PACAP has been shown to play a role in cell proliferation and 
differentiation in numerous normal and tumorous cells and 
expression of PACAP or its receptors is suggested to correlate 
with tumor growth and differentiation (108–110). It has also 
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been shown that expression of the peptide and/or its recep-
tors show marked changes in certain tumor types either in the 
tumor itself or in peritumoral areas (111–115). Little is known 
about the connection between gastric tumors and PACAP, but 
some data indicate that PACAP may play a regulatory role in 
gastric tumor biology. Studying human tumors, it has been 
revealed that PACAP receptors are expressed in gastric cancer. 
Overexpression of PACAP receptors has been reported in vari-
ous types of cancer, including stomach cancer in about half of 
the examined cases (114–117). Schulz et al. could detect VPAC1 
and VPAC2 receptors in gastric cancer (118, 119), while they 
could not detect PAC1 expression in gastric tumors.
PACAP is linked to proliferative signaling pathways and 
tumor growth (120). It was proposed that, similarly to solid 
tumors, PAC1 receptors are expressed on neuroendocrine tumor 
cells and may mediate biological effects induced by PACAP, such 
as secretion and growth (120). In Mastomys ECL cells, trans-
formation was induced by histamine 2 receptor blockade (22). 
During the process of mucosal hyperplasia induced by endog-
enous hypergastrinemia, PACAP-LI increased significantly and 
was identified primarily in a linear-punctuated pattern. In the 
stage of carcinoid tumor formation, PACAP-LI was present in 
striking abundance and mostly presented in the basket-like pat-
tern. Indeed, most of the basket-like IR was identified within 
neoplastic lesions. In the fundus, PACAP immunoreactivity 
significantly increased in the tumor mucosa compared to 
controls (22). Investigation of the receptor subtypes revealed 
that the expression levels of PAC1 and VPAC2 were modestly 
upregulated in tumor ECL cells compared with naive cells, but 
that of VPAC1 receptor subtype appeared to be downregulated 
(22). PACAP induced the proliferation of transformed ECL cells, 
and this effect was stronger than that of TGFα or gastrin (22). 
These effects could be completely antagonized by PACAP6–38 
and to a lesser extent by a VPAC1 antagonist (22). Although it 
is not known whether this process plays a role in human gastric 
tumor formation, these results indicate that PACAP potently 
modulates ECL cell proliferation and is involved in ECL cell 
transformation. The growth of the neuroendocrine-derived 
ECL cells in the stomach has been shown to be influenced by 
PACAP (121). Lieu et  al. (120) have demonstrated that PAC1 
receptors are expressed in the well-established neuroendocrine 
cell-derive BON cell line. The authors propose that PACAP may 
regulate the biological release of peptides and serotonin from 
BON cells and that, like in solid tumors, PACAP could poten-
tially stimulate the growth of BON cells (120). These few data 
indicate that PACAP may play a role in the growth of different 
types of stomach cancer.
MOTiliTY DiSORDeRS
In spite of the large amount of data regarding actions of PACAP 
on motility, very little is known about motility disorders associ-
ated with PACAP signaling. The role of endogenous PACAP in 
gastric motility is supported by observations in PACAP KO mice: 
relaxation effect of PACAP is reduced by about 50% in muscle 
strips prepared from PACAP knockout mice (85). These find-
ings were subsequently confirmed by others: mice deficient in 
PACAP have decreased relaxation in the stomach (86). Although 
no in  vivo data are available for PACAP, VIP knockout mice 
have been shown to develop intestinal motility dysfunction, 
similar to that observed in human Hirschprung’s disease (122). 
Furthermore, dystrophic mice have been reported to develop 
gastrointestinal motor disorders, where PACAP6–38 abolished 
off-relaxations and also caused a reduction in amplitude of the 
contractile responses and efficacy of PACAP 6–38 on the excita-
tory responses was lower in strips from dystrophic mice than in 
wild types (123). The observed stronger peptidergic modulatory 
action can contribute to the altered gastric contractile responses 
in this motility disorder (123). Whether these alterations are also 
present in human conditions, awaits further investigations.
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